HDAC6 and plasma cell myeloma: RCL selectively inhibited HDAC6, induced dose-dependent cell death in several sensitive and resistant MM cell lines, and triggered synergistic myeloma cell cytotoxicity when combined with BTZ or with carfilzomib both in vitro and in vivo (Table 2) [143, 144].